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Gram-positive bacterial products such as peptidoglycan (PGN) and lipoteichoic acid (LTA) are potent
stimulators of innate inflammatory responses. We previously reported that lipopolysaccharide (LPS), a major
biologically active agent of gram-negative bacteria, induces a proinflammatory response via the Toll-like
receptor (TLR) 4 in hepatic stellate cells (HSCs). Here we investigated the mechanism of proinflammatory action
by PGN and LTA in activated human HSCs. Following treatment with either TNF-a or IL-1b, expression of TLR2
and CD14 was determined by real-time PCR and Western blotting. NF-jB activation was assessed by NF-jB-
driven luciferase assay and electrophoretic mobility shift assay. Interleukin-8 (IL-8) from culture supernatant
was measured by ELISA. Activated human HSCs express TLR2 and CD14, which are receptors for PGN and LTA
signaling. TNF-a and IL-1b significantly upregulated the expression of TLR2 mRNA and protein in HSCs. PGN
and LTA induced NF-jB activation and stimulated production of IL-8 in HSCs. Pretreatment with TNF-a or IL-1b
augmented NF-jB activation and IL-8 production in response to PGN or LTA. Both PGN- and LTA-induced NF-
jB activation and IL-8 secretion were completely inhibited by anti-TLR2 blocking antibody (T2.5). These
findings suggest that TNF-a or IL-1b primed HSCs enhance the production of IL-8 in response to PGN and LTA
through augmentation of the TLR2 system.
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Chronic and repeated hepatic inflammation results
in hepatic fibrosis and liver cirrhosis. A variety of
liver injuries cause hepatocyte apoptosis, necrosis,
and Kupffer cell activation, resulting in subsequent
production of inflammatory cytokines. Various in-
flammatory cytokines activate and transform quies-
cent hepatic stellate cells (HSCs) into activated
HSCs. Over-and-above their contractile properties,
activated HSCs proliferate, migrate, secrete inflam-
matory cytokines and chemokines, and produce
type I collagen.1 In addition, it has been reported
that HSCs can uptake and present foreign antigens,
and participate in the innate immune response in
the liver.2
Toll-like receptors (TLRs) are type I integral
membrane glycoproteins, which recognize patho-
gen-associated molecular patterns present in micro-
bial components.3 So far, 13 members of the TLR
family have been identified in mammals, and
stimulation of different TLRs induces distinct
patterns of gene expression, which leads to the
activation of innate immunity.4 TLRs have a con-
served cytoplasmic domain, Toll/IL-1R (TIR), and a
variable extracellular domain which contains leu-
cine-rich repeats that determine the responsiveness
to a specific pathogen.5,6 TLR2 is located on the
cell surface and is recruited to the phagosome
after activation by its reactive ligand; this could
be a lipoprotein, peptidoglycan, lipoteichoic acid,
lipoarabinomannan, atypical liposaccharide, or
heat-shock protein 70.7–9 Thus, intracellular locali-
zation of TLR2 is a feature of exposure to its ligands.
Activation of TLR2 leads to the recruitment of
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MyD88, an adaptor molecule, which then facilitates
the association of IL-1 receptor-associated kinase
(IRAK) 4 with MyD88. IRAK4 phosphorylates
IRAK1, and activated IRAK1 autophosphorylates
and enables TNF receptor-associated factor (TRAF)
6 to bind this complex. TRAF6 then disengages and
translocates to the cytoplasm to activate the IKK
(inhibitor of nuclear factor kB kinase) complex and
MAPKs resulting in the release of nuclear factor kB
(NF-kB) and c-Jun N-terminal kinase (JNK).3,10
In cirrhotic rats and human patients, intestinal
bacterial overgrowth occurs, including not only
gram-negative enteric bacteria but also gram-posi-
tive bacteria.11 Cirrhosis is also associated with
increased permeability of the intestinal mucosal
barrier and facilitated bacterial translocation into
the portal vein.12,13 We previously reported that
human HSCs expressed TLR4 and CD14, and
showed a strong inflammatory reaction in response
to lipopolysaccharide (LPS), a major cellular com-
ponent of gram-negative bacteria.14 LPS-induced
HSC and Kupffer cell activation is now regarded as
an important mechanism of liver injury, especially
in alcoholic liver diseases.14–16 Hence, there is a high
likelihood that HSC will be exposed to bacterial
products in the setting of chronic liver disease.
Riordan et al17 reported that the expression of
TLR2 was upregulated in peripheral blood mono-
nuclear cells (PBMCs) and was significantly corre-
lated with serum TNF-a level in cirrhotic patients,
suggesting a potential role of TLR2-mediated in-
flammation in the development of liver injury. In
addition, Brun et al18 recently reported that lipotei-
choic acid and N-acetyl muramyl peptide induced
TGF-b, IL-6, and MCP-1 in murine HSCs, suggesting
the substantial role of gram-positive bacterial
products in hepatic inflammation and fibrosis.
However, the molecular mechanisms involved in
the gram-positive bacterial product induction of
inflammatory signaling in human HSCs are still
unknown.
It has been reported that IFN-g or bacteria such as
Propionibacterium acnes can enhance the LPS-
induced inflammatory response by a selective
priming of mononuclear phagocytes and fibro-
blasts.19–22 Those priming effects were mediated by
an upregulation of TLR4 and/or other downstream
signaling molecules including MD2, CD14, and
MyD88.20–23 These results are intriguing with regard
to hepatic injury and inflammation because many
proinflammatory cytokines, such as TNF-a, are
upregulated in patients with liver cirrhosis and
liver injury.24,25 Therefore, we hypothesized that the
inflammatory reaction induced by the gram-positive
bacterial cell wall components is also enhanced in
an injured liver. In this study, we examined the
inflammatory response induced by the gram-posi-
tive bacterial products, PGN and LTA, in activated
human HSCs, and investigated further the under-
lying mechanism of cytokine-induced upregulation
of PGN or LTA-induced inflammatory response.
Materials and methods
Reagents
PGN from Staphylococcus aureus, PGN from Bacil-
lus subtilis, and LTA from Streptococcus pyogenes
were purchased from Sigma (St Louis, MO). LPS
levels were measured by Limulus Amebocyte lysate
assay (Cambrex, Rutherford, NJ) and were less than
10 ng/ml of PGN or LTA stock solution. All stimula-
tions were conducted in serum-free conditions to
rule out possible contamination by LPS. LPS from
Escherichia Coli serotype O127:B8 (phenol ex-
tracted and chromatographically purified by gel
filtration, protein content o1%) was purchased
from Sigma (St Louis, MO). Human recombinant
TNF-a and IL-1b were purchased from R&D Systems
(Minneapolis, MN). Polymyxin B was purchased
from Sigma. Mouse anti-human TLR2 blocking Ab
(T2.5) and isotype IgG1 Ab were obtained from
eBioscience (San Diego, CA).
Activated Human HSC Cell Line (hTERT) and Primary
Human HSC Culture
We used an immortal human HSC cell line estab-
lished by functional expression of the telomerase
catalytic subunit (human telomerase reverse tran-
scriptase or hTERT) throughout most of the experi-
ments because telomerase-positive HSCs exibited
morphological and functional characteristics of
activated human HSCs. This included the expres-
sion of smooth muscle a-actin, glial fibrillary acidic
protein (GFAP), and Type I collagen, as previously
well characterized by Schnabl et al.26–28 Telomerase-
positive HSCs were seeded on uncoated plastic
tissue culture dishes and cultured in DMEM (Life
Technologies, Grand Island, NY) supplemented
with 10% heat inactivated FBS and standard
antibiotics in a 95% air and 5% CO2 humidified
atmosphere at 371C. For RT-PCR experiment of TLR2
and CD14, primary human HSCs were isolated by a
two-step collagenase perfusion from surgical speci-
mens of a normal human liver or a HCV-induced
human cirrhotic liver as described previously.26
All tissues were obtained by qualified medical
staff, with donor consent and the approval of the
Columbia University Ethics Committee. HSC purity
was assessed microscopically and by using the
autofluorescence property of the stored retinoids in
HSCs. Cell viability was determined using Trypan
blue exclusion staining. HSC populations were more
than 96% pure and viable. Isolated primary HSCs
were seeded on uncoated plastic tissue culture
dishes and cultured in DMEM (Life Technologies,
Grand Island, NY) supplemented with 10% heat
inactivated FCS and standard antibiotics in 95% air
and 5% CO2 humidified atmosphere at 371C. After 2
days in culture, HSCs from normal human liver had
a quiescent phenotype, and after 14 days, the HSCs
had an activated phenotype as described.29 The
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human monocytic cell line THP-1 (from American
Type Culture Collection) was cultured in RPMI
medium with 10% FCS. THP-1 cells were differ-
entiated by treatment with 10 ng/ml of PMA for 18 h.
Western-Blot Analysis
Whole-cell extracts were prepared from telomerase-
positive human HSCs using Triton lysis buffer
containing protease and phosphatase inhibitors, as
described.29 Forty micrograms of protein were
electrophoresed on 10% SDS-polyacrylamide gels.
The gels were then blotted onto a nitrocellulose
membrane. Rabbit anti-human fibulin-2 (Santa Cruz
Biotechnology, Santa Cruz, CA), rabbit anti-human
type I collagen (Biodesign, Saco, ME), mouse anti-
human a smooth muscle actin (a-SMA) (Dako,
Glostrup, Denmark), rabbit anti-human TLR2
(eBioscience, San Diego, CA), rabbit anti-human
CD14 (Santa Cruz Biotechnology), and mouse anti-
human b-actin (Abcam, Cambridge, MA) antibodies,
all diluted 1:1000, were used to detect immuno-
reactive fibulin-2, type I collagen, a-SMA, TLR2,
CD14, and b-actin, respectively, using an enhanced
chemiluminescence light (ECL) detecting kit (Amer-
sham Pharmacia Biotech, Piscataway, NJ) as pre-
viously described.29 JAR cell lysate (Santa Cruz
Biotechnology) was used as a positive control for
fibulin-2.
Reverse Transcription-Polymerase Chain Reaction
(RT-PCR) Analysis
Total RNA was isolated from an activated human
HSC cell line (hTERT), quiescent or in vitro culture-
activated primary human HSCs (from normal liver),
in vivo-activated primary human HSCs (from HCV-
induced cirrhotic liver), and differentiated THP-1
cells by the TRIzol method (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions.
One microgram of total RNA was reverse transcribed
using dT15-oligonucleotide and Moloney murine
leukemia virus reverse transcriptase (Perkin-Elmer/
Applied Biosystems, Foster City, CA) in a 25-ml total
reaction volume. One microliter of the reverse
transcriptase reaction was subjected to PCR analysis
to measure the mRNA levels of TLR2, CD14, and b-
actin. PCR amplification was performed with Taq
polymerase (Invitrogen, Carlsbad, CA) for 30 cycles
at 951C for 45 s, 541C for 45 s, and 721C for 1 min for
TLR2, and for 30 cycles at 921C for 45 s, 561C for
45 s, and 721C for 1 min for CD14 and b-actin.
Primers for TLR2 were 50-GCCAAAGTCTTGATTGA
TTGG sense and 50-TGGAAGTTCTCCAGCTCCTG
antisense. PCR primers for CD14 were 50-GGTGCC
GCTGTGTAGGAAAGA sense and 50-GGTCCTCGAG
CGTCAGTTCCT antisense. PCR primers for b-actin
were 50-CCAACCGCGAGAAGATGACC sense and
50-GATCTTCATGAGGTAGTCAGT antisense.
Quantitative Real-Time PCR
The mRNA of TLR2 and CD14 were estimated by
quantification of TLR2, CD14, and glyceraldehydes-
3-phosphate dehydrogenase (GAPDH) cDNA by the
TaqMan real-time PCR method using a LightCycler
(Roche, Mannheim, Germany). Primers for TLR2,
CD14, and GAPDH were designed and synthesized
by TIB MOLBIOL (Berlin, Germany) (Table 1). PCR
conditions were as follows: pre-denaturation step
for 10 min at 951C followed by 45 cycles at 951C and
541C for 10 s each for TLR2, 951C and 581C for 10 s
each for CD14, and 951C and 491C for 10 s each for
GAPDH. The amplification protocol was followed
by a cooling period of 401C for 30 s. The reaction
mixture for the TaqMan probe assay contained 1ml
of LightCycler FastStart Enzyme (10 conc), 2 ml of
10 pM LightCycler FastStart Reaction Mix Hyb-
Probe, 2.4 ml of 25 mM MgCl2, 0.5 ml of 5 mM forward
and reverse primers, 1 ml cDNA, and 13.1 ml water for
a total volume of 20ml. The fluorophore of the probe
is 6-FAM in the 50-position, which is quenched by
TAMRA in the 30-position when the probe is intact
(Eurogentec, Seraing, Belgium). Fluorescence is
generated after the probe is hybridized and digested
by the 50exonuclease activity of Taq polymerase. All
data were analyzed using Lightcycler software
version 4.0. GAPDH was used for normalization of
all experiments.
Immunofluorescent Staining of TLR2
Thirty thousand HSCs were plated onto an uncoated
six-well plate and treated as described. After 24 h of
TNF-a (10 ng/ml) or IL-1b (5 ng/ml) treatment, cells
were fixed in ice-cold methanol for 10 min, washed
three times with PBS, and blocked with 10% normal
goat serum in PBS. For the detection of human
TLR2, cells were incubated with rabbit anti-human
TLR2 (Santa Cruz Biotechnology, Santa Cruz, CA)
primary antibody at 1:100 in blocking solution
for 2 h, and rhodamin-conjugated goat anti-rabbit
Table 1 Primer sequences for quantitative real-time PCR
experiments
Primer Sequence
TLR2
Sense (50–30) TGG TAG TTG TGG GTT GAA GCA
Antisense (50–30) TAC CAT TGC GGT CAC AAG ACA
TaqMan probe (50–30) CTT GGA GAG GCT GAT GAT GAC CCC
CD14
Sense (50–30) GAC TTA TCG ACC ATG GAG CG
Antisense (50–30) GAA ATC TTC ATC GTC CAG CTC A
TaqMan probe (50–30) CAG AGA CGT GCA CCA GCG GCA GCA G
GAPDH
Sense (50–30) GAA GGT GAA GGT CGG AGT C
Antisense (50–30) GAA GAT GGT GAT GGG ATT TC
TaqMan probe (50–30) CAA GCT TCC CGT TCT CAG CCT
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secondary antibody (Pierce, Rockford, IL) at 1:100
for 1 h. The cells were then visualized on an
Olympus microscope (Olympus, Melville, NY)
using a digital imaging system (Molecular Dy-
namics, Sunnyvale, CA).
NF-jB Responsive Luciferase Assay
Recombinant adenoviral vectors expressing a luci-
ferase reporter gene driven by NF-kB transcriptional
activation (Ad5NF-kBLuc),14 were used for the
assessment of NF-kB transcriptional activation.
HSCs were infected with Ad5NF-kBLuc (multi-
plicity of infection 500) for 12 h in DMEM contain-
ing 0.5% FBS. After infection, the medium was
exchanged with fresh medium containing 0.5%
FBS, and the culture was continued for an addi-
tional 8 h before performing the individual experi-
ments. A luciferase assay kit with luciferase cell
culture lysis buffer (Promega, Madison, WI) was
used to measure NF-kB-mediated transcriptional
induction, according to the manufacturer’s protocol.
All measurements of luciferase activity (relative
light units) were normalized to the protein concen-
tration.
Electrophoretic Mobility Shift Assay (EMSA)
HSCs were stimulated with PGN (S. aureus) or LTA
(B. subtilis) (10 mg/ml) for 1 h with or without
pretreatment with TNF-a (10 ng/ml) for 24 h. Stimu-
lation of cells with IL-1b (5 ng/ml) for 15 min was
used as a positive control. Nuclear extracts were
prepared as previously described.30 Five micro-
grams of protein was incubated with a radiolabeled
probe containing the NF-kB consensus site (top: 50-
AGTTGAGGGGACTTTCCCAGGC-30; bottom: 50-
GCCTGGGAAAGTCCCCTCAACT-30), separated by
electrophoresis, and then analyzed by autoradiogra-
phy as described previously.31 A 100-fold molar
excess of cold oligonucleotide was added as a
competition experiment.
IL-8 Enzyme-Linked Immunosorbent Assay
After a 48-h serum starvation, HSCs were stimulated
with PGN (10 mg/ml) or LTA (10 mg/ml) with or
without TNF-a (10 ng/ml) for 24 h. IL-8 secretion
into the culture media by HSCs were measured by
ELISA according to the manufacturer’s instruction
(R & D Systems, Minneapolis, MN).
Statistics
Data were analyzed by the Student’s t-test and two-
way ANOVA using the Tukey method. Differences
between sets of data were considered to be statisti-
cally significant when Pr0.05.
Results
Telomerase-Positive Human HSCs and Primary
Human HSCs Express TLR2 and CD14
The expression of activated HSC markers including
type I collagen and a-SMA, and a marker of
myofibroblast fibulin-2 in the telomerase-positive
human HSC cell line (hTERT) was first assessed by
Western blotting. Telomerase-positive human HSCs
expressed type I collagen and a-SMA but not fibulin-
2, suggesting that telomerase-positive human HSCs
correspond to activated human HSCs (Figure 1a).
The expression of PGN or LTA receptor molecules,
including TLR2 and CD14, in human HSCs was
assessed by RT-PCR. In telomerase-positive human
HSCs (hTERT), mRNA encoding TLR2 and CD14
was clearly detected. THP-1 cells, a human mono-
cyte cell line, served as a positive control (Figure 1b,
left panel). We also checked the mRNA expression
of TLR2 and CD14 in primary human HSCs. In
quiescent HSCs, TLR2 mRNA was weakly detected;
however, CD14 mRNA was not detected. The
mRNAs for TLR2 and CD14 were clearly detected
in both in vitro culture-activated HSCs (from normal
Figure 1 Characterization of telomerase-positive HSCs and
expression of peptidoglycan and lipoteichoic acid receptors in
primary human HSCs. (a) The expression of type I collagen,
a-SMA, and fibulin-2 in a telomerase-positive human HSC cell
line (hTERT) was assessed by Western blotting. JAR cell lysate
was used as a positive control for fibulin-2. (b, c) TLR2 and CD14
mRNA expression was assessed by RT-PCR in telomerase-positive
HSC cell line and primary human HSCs. (b) Total RNA was
obtained from an activated human HSC cell line (hTERT) or from
differentiated THP-1 cells. THP-1 cells were differentiated by
treatment with 10 ng/ml of PMA for 18 h, and were used as a
positive control. (c) Total RNA was obtained from quiescent
human HSCs or in vitro culture-activated human HSCs (from
normal liver), and in vivo activated human HSCs (from HCV-
induced cirrhotic liver).
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liver) and in vivo activated HSCs (from HCV-
induced cirrhotic liver) (Figure 1b, right panel).
Separately, TNF-a and IL-1b Upregulate the
Expression of TLR2 in HSCs
We performed quantitative real-time PCR to quanti-
tate the change of TLR2 and CD14 mRNA expression
during TNF-a, IL-1b, LPS, and PGN stimulation.
Real-time PCR showed that TNF-a strikingly in-
creased TLR2 mRNA expression 149-fold at 12 h,
and 572-fold 24 h after stimulation compared to
baseline levels (Figure 2a); on the other hand, TNF-a
only weakly upregulated CD14 expression, by 3.7-
fold, at 24 h (Figure 2b). IL-1b upregulated TLR2
mRNA expression to a 14.1-fold maximum at 12 h
followed by a decrease in mRNA expression at 24 h
after stimulation (Figure 2a), and IL-1b upregulated
CD14 expression to a 9.8-fold maximum after 24 h of
stimulation (Figure 2b). LPS and PGN from S.
aureus did not significantly upregulate TLR2 and
CD14 mRNA expression in HSCs.
We looked at changes of TLR2 and CD14 expres-
sion in response to TNF-a or IL-1b in HSCs by
Western blotting (Figure 3a). The TLR2 protein level
was upregulated at 24 and 48 h after stimulation
with TNFa or IL-1b in HSCs. However, the expres-
sion of CD14 protein was not significantly changed
after TNF-a or IL-1b treatment. Immunofluorescent
staining was performed to investigate the change of
TLR2 protein expression after cytokine stimulation.
Activated human HSCs expressed TLR2 protein
mainly in the cytoplasm (Figure 3c). After 24 h of
TNF-a (10 ng/ml) or IL-1b (5 ng/ml) stimulation,
TLR2 expression was markedly upregulated (Figure
3d, e). These results demonstrated that TLR2, a
major receptor component of gram-positive bacterial
products such as peptidoglycan and lipoteichoic
acid, was significantly upregulated by TNF-a and
IL-1b.
Peptidoglycan and Lipoteichoic Acid Activate
NF-jB in HSCs
To investigate whether PGN and LTA induce NF-kB
activation, we performed a NF-kB-driven luciferase
reporter assay. PGN from S. aureus, PGN from B.
subtilis and LTA from S. pyogenes induced NF-kB
transcriptional activity 1.8-fold, 2.9-fold and 2.8-
fold compared to an untreated control, respectively
(Po0.01) (Figure 4). Polymyxin B, a LPS inhibitor,
did not inhibit PGN- or LTA-induced NF-kB activa-
tion in HSCs. In addition, LPS did not activate NF-
kB in serum-free conditions, demonstrating that the
PGN- or LTA-induced NF-kB activation was not
mediated by contaminating LPS.
TNF-a and IL-1b Enhance Peptidoglycan- and
Lipoteichoic Acid-Induced NF-jB Activation in HSCs
We examined whether priming with inflammatory
cytokines, such as TNF-a or IL-1b, modulates NF-kB
transcriptional activation in activated human HSCs.
HSCs were treated with TNF-a (10 ng/ml) or IL-1b
(5 ng/ml) for 24 h, and then stimulated with PGN or
LTA for 8 h. As shown in Figure 5a, TNF-a or IL-1b
primed HSCs showed significantly greater NF-kB
transcriptional activation than nonprimed HSCs in
response to PGN or LTA. Next, we examined NF-kB
nuclear binding activity using EMSA. Separately,
PGN and LTA weakly induced NF-kB nuclear
binding, and interestingly, preincubation of HSCs
with TNF-a for 24 h significantly upregulated PGN-
and LTA-induced NF-kB binding activity (Figure
5b). These results suggest that cytokines such as
Figure 2 TLR2 and CD14 mRNA expression after stimulation
with TNF-a or IL-1b for different periods of time in HSCs.
Quantitation of TLR2 (a) or CD14 mRNA (b) expression for
different periods of time after TNF-a (10 ng/ml), IL-1b (5 ng/ml),
LPS (1mg/ml), or PGN stimulation from S. aureus (10mg/ml)
under serum-free conditions in activated HSCs was done by
quantitative real-time RT-PCR. Data represent the mean7s.d. of
three independent experiments performed in duplicate, and are
expressed as fold-increase over cells at time point zero. *:
Po0.01, when compared with HSCs stimulated with TNF-a at
time point zero, w: Po0.01, when compared with HSCs stimulated
with IL-1b at time point zero.
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TNF-a and IL-1b enhance PGN- and LTA-induced
NF-kB activation in activated human HSCs.
TLR2 Blocking Antibody Inhibits NF-jB Activation
and IL-8 Production by TNF-a-Primed and Nonprimed
HSCs in Response to Peptidoglycan or Lipoteichoic
Acid
We examined whether TNF-a-primed or nonprimed
HSCs activate NF-kB and produce IL-8 through
TLR2. A NF-kB driven reporter assay showed that
peptidoglycan- and lipoteichoic acid-induced NF-
kB activation was almost completely suppressed to a
baseline level by preincubation with TLR2 blocking
Ab (T2.5), but not with isotype IgG1 Ab, both in
nonprimed and TNF-a-primed HSCs (Figure 6a, b).
As shown by ELISA (Figure 7a–c), the peptidogly-
can- and lipoteichoic acid-induced IL-8 secretion in
HSCs was completely inhibited by preincubation
with TLR2 blocking Ab (T2.5), but not with isotype
IgG1 Ab. After priming HSCs by pretreatment with
TNF-a for 24 h, peptidoglycan- and lipoteichoic
acid-induced IL-8 secretion was further enhanced,
Figure 3 Upregulation of TLR2 protein expression in activated human HSCs in response to TNF-a or IL-1b. (a) Quantitation of TLR 2 and
CD14 protein expression for different periods of time after TNF-a (10 ng/ml) or IL-1b (5 ng/ml) stimulation in activated HSCs was done by
Western blotting. (b–e) Immunofluorescent staining was used to assess TLR2 protein expression in activated human HSCs. Cells were
cultured in DMEM without serum. Cells were treated for 24 h as follows: (b, c) serum-free DMEM, (d) TNF-a (10 ng/ml), and (e) IL-1b
(5 ng/ml). After 24 h of stimulation, (b) cells were fixed and stained with secondary antibody only, or (c–e) cells were stained with rabbit
anti-human TLR2 primary antibody and goat anti-rabbit rhodamin-conjugated secondary antibody.
PGN- or LTA- induced inflammation in HSCs
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but IL-8 secretion was completely inhibited by
preincubation with TLR2 blocking Ab (T2.5) (Figure
7a–c). These results demonstrated that PGN and LTA
have a direct proinflammatory action through TLR2
in activated human HSCs.
Discussion
Chronic hepatic inflammation results in fibrosis of
the liver. Cytokines, chemokines, and growth fac-
tors, such as TNF-a, IL-1b, IL-6, interferon-g, IL-8,
macrophage inflammatory protein-1, macrophage
chemoattractant factor-1, and transforming growth
factor-b, are all upregulated upon chronic hepatic
inflammation, and these mediators cause HSC
activation that results in liver fibrosis.32 Based on
the importance of chronic inflammation in the
development of hepatic fibrosis, anti-inflammatory
therapy is a potential therapeutic modality for the
prevention or reversal of hepatic fibrosis. Hepatic
stellate cells are a critical cell type for the develop-
ment of hepatic fibrosis. In this study we used
telomerase-positive human HSCs because they
Figure 4 Peptidoglycan or lipoteichoic acid induces NF-kB
transcriptional activation in activated human HSCs. NF-kB
transcriptional activation was assessed with NF-kB-driven luci-
ferase assay. Activated human HSCs were infected with Ad5NF-
kBLuc (MOI 500) for 12 h in DMEM containing 0.5% FCS. At 20 h
post-infection, HSCs were stimulated with PGN (S. aureus)
(10mg/ml), PGN (B. subtilis) (10mg/ml), LTA (S. pyogenes)
(10mg/ml), TNF-a (10 ng/ml), or LPS (1mg/ml) for 8 h in serum-
free conditions with or without pretreatment of Polymyxin B
(10 IU/ml) for 30 min. Cells were lysed, and NF-kB-mediated
luciferase activity was quantified. Data represent the mean7s.d.
of three independent experiments performed in duplicate, and are
expressed as fold-increase over unstimulated cells. All measure-
ments of luciferase activity were normalized to the protein
concentration. *, w: Po0.01, when compared with unstimulated
HSCs.
Figure 5 Enhanced NF-kB activation in TNF-a- or IL-1b-primed
HSCs after stimulation with peptidoglycan or lipoteichoic acid.
(a) Activated human HSCs were infected with Ad5NF-kBLuc
(MOI 500) for 12 h in DMEM containing 0.5% FCS. HSCs were
then incubated in serum-free DMEM with TNF-a (10 ng/ml) or IL-
1b (10 ng/ml) for 24 h. After washing three times, HSCs were
stimulated with media, PGN (S. aureus) (10mg/ml), PGN (B.
subtilis) (10mg/ml), or LTA (S. pyogenes) (10mg/ml) for 8 h in
serum-free conditions. Data represent the mean7s.d. of three
independent experiments performed in duplicate, and are
expressed as fold-increase over unstimulated cells. All measure-
ments of luciferase activity were normalized to the protein
concentration. *, w, z: Po0.01, when compared to control HSCs
without stimulation; y: Po0.01, unprimed HSCs vs TNF-a-primed
HSCs; **: Po0.01, unprimed HSCs vs IL-1b-primed HSCs; #:
Po0.01, TNF-a-primed HSCs vs IL-1b-primed HSCs. (b) Activated
human HSCs were incubated with DMEM alone (lanes 1–3) or
with TNF-a (10 ng/ml) for 24 h (lanes 4–8). Cells were then treated
as follows: lanes 1,4, DMEM; lanes 2,5, PGN from S. aureus
(10mg/ml); lanes 3,6, LTA from S. pyogenes (10mg/ml); and lane 7,
IL-1b (5 ng/ml). Lanes 8 is the same as lane 5 with the addition of
a 100-fold molar excess of cold oligonucleotide as a competitor.
Nuclear extracts (5 mg) were assayed for NF-kB binding activity by
EMSA using a radiolabeled consensus NF-kB site as a probe. A
representation of three independent experiments is shown. *, w:
Po0.01, when compared to control HSCs without stimulation; z:
Po0.01, unprimed HSCs vs TNF-a-primed HSCs.
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proved to have morphological and functional char-
acteristics of activated HSCs. Telomerase positive
human HSCs expressed Type I collagen and a
smooth muscle actin but not fibulin 2, suggesting
that telomerase-positive HSCs correspond to acti-
vated HSCs but not to myofibroblasts.33
TLRs, a family of phylogenetically conserved
receptors, have attracted particular interest because
of their functions in the regulation and linking of
innate immune and inflammatory processes. We
previously demonstrated that TLR4, a receptor for
lipopolysaccharide (LPS), was expressed in human
HSCs and demonstrated that LPS has a direct
proinflammatory action on HSCs via TLR4-mediated
signaling. These findings suggest that bacterial
product-induced inflammatory signaling in HSCs
may be important, and could be a therapeutic target
for hepatic inflammation and subsequent fibrosis.
Increased portal bacteremia, including gram-posi-
tive and gram-negative bacteria, occurs in patients
with chronic liver diseases. Hence, this study
examined the effect of gram-positive bacterial
products on HSCs. Peptidoglycan and lipoteichoic
acid are major proteins on the cell wall of gram-
positive bacteria. TLR2 is a receptor for several
ligands such as lipoprotein, peptidoglycan, lipotei-
choic acid, lipoarabinomannan, atypical liposac-
charide, and heat-shock protein 70.7–9 CD14 was
shown to be a co-receptor for TLR4 and TLR2. CD14
contains discrete binding sites that are different for
LPS and PGN.34,35 It has been reported that gram-
positive PGN and LTA trigger cytokine release from
innate immune cells.36,37 In this study, we investi-
gated the role of gram-positive bacterial products in
the inflammation of hepatic stellate cells. Our study
demonstrated that both telomerase-positive human
HSCs (hTERT) and primary human HSCs express
TLR2 and CD14, which are receptors for PGN and
LTA signaling. The findings that TLR2 and CD14 are
upregulated in both in vitro and in vivo activated
HSCs compared to quiescent HSCs suggest that
innate inflammatory actions in response to gram
positive bacterial products are coordinantly upregu-
lated in activated HSCs. Our study showed that
peptidoglycan and lipoteichoic acid from different
strains of gram-positive bacteria weakly induced
Figure 6 Peptidoglycan- or lipoteichoic acid-induced NF-kB
activation is inhibited by TLR2 blocking antibody in TNF-a-
primed and nonprimed HSCs. Activated human HSCs were
infected with Ad5NF-kBLuc (MOI 500) for 12 h in DMEM
containing 0.5% FCS. HSCs were then incubated with serum-
free DMEM or TNF-a (10 ng/ml) for 24 h. After washing three
times, HSCs were stimulated with: (a) serum-free media, PGN
from S. aureus (10mg/ml) via preincubation with media, anti-
TLR2 bloking Ab (20mg/ml), or IgG1 Ab for 30 min; or (b) serum-
free media, LTA from S. pyogenes (10mg/ml) via preincubation
with media, anti-TLR2 bloking Ab (20mg/ml), or IgG1 Ab for
30 min. Cells were lysed, and NF-kB-mediated luciferase activity
was quantified. Data represent the mean7s.d. of three indepen-
dent experiments performed in duplicate and are expressed as
fold-increase over unstimulated cells. All measurements of
luciferase activity were normalized to the protein concentration.
*, z: Po0.01, when compared to control HSCs without stimula-
tion; w, y: Po0.01, compared to HSCs with stimulation after
preincubation with IgG1 Ab;**: Po0.01, unprimed HSCs vs TNF-
a-primed HSCs.
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NF-kB in human HSCs, which is a major proin-
flammatory signaling mediator. In addition, PGN
and LTA significantly induced proinflammatory IL-8
secretion in activated human HSCs. The minimal
active concentration of PGN or LTA for proinflam-
matory response in HSCs was 1mg/ml, which was
100 times higher than that of LPS (as low as 1 ng/
ml). These findings were comparable to previous
studies using monocytes.9,35
It is noteworthy that the priming of HSCs with
TNF-a or IL-1b significantly upregulated the expres-
sion of TLR2 mRNA and protein in human HSCs.
There was some discrepancy of time course between
TLR2 mRNA expression and protein expression in
IL-1b-stimulated HSCs. We think that the discre-
pancy may be caused by a different signaling
pathway of IL-1b compared to TNFa, and post-
transcriptional or post-translational modification of
TLR2 mRNA in IL-1b-stimulated HSCs. PGN- or
LTA-induced NF-kB activation and IL-8 secretion
was further enhanced by pretreatment of HSCs with
TNF-a or IL-1b. In chronic hepatic inflammation,
various proinflammatory cytokines are upregulated.
Induction and upregulation of TLR2 by inflamma-
tory cytokines, such as TNF-a and IL-1b, in HSCs
may have important clinical implications for hepatic
inflammation and fibrosis in liver cirrhosis patients
due to its rendering HSCs more sensitive to micro-
bial ligands in portal circulation that specifically
use TLR2.
Preincubation of HSCs with TLR2 blocking anti-
body completely inhibited PGN- or LTA-induced
NF-kB activation and IL-8 secretion in TNF-a-
primed and unprimed HSCs. These results suggest
that TLR2 is critical in PGN- or LTA-induced
inflammatory action in HSCs, and the upregulation
of critical components of PGN or LTA signaling is, at
least in part, a mechanism of response enhancement
by TNF-a or IL-1b. It was reported that priming or
concomitant exposure of mononuclear phagocytes
to IFN-g dramatically increased their responsiveness
to LPS,19 and the molecular basis for the priming
and synergism of IFN-g was shown as the upregula-
tion of TLR4 and MD2 mRNA and surface expres-
sion on mononuclear phagocytes.23 In human
endothelial cells, LPS and TNF-a separately induce
TLR2 upregulation through TLR4-, MyD88-, and NF-
kB-dependent signaling.38 Additional mechanisms
besides the upregulation of TLR2 may play a role in
enhancing the response of TNF-a and IL-1b in HSCs
to PGN/LTA. Recently, receptor synergism between
several members of the TLR family and the adeno-
sine A2a receptor has been reported.
39 Further
research is needed to investigate whether synergy
Figure 7 Peptidoglycan- or lipoteichoic acid-induced IL-8 production is inhibited by TLR2 blocking antibody in TNF-a-primed and
nonprimed HSCs. HSCs were incubated in serum-free DMEM or TNF-a (10 ng/ml) for 24 h. After washing three times, HSC were
stimulated with: (a) serum-free media, PGN from S. aureus (10mg/ml) via preincubation with media, anti-TLR2 bloking Ab (20mg/ml), or
IgG1 Ab for 30 min; (b) serum-free media, PGN from B. subtilis (10mg/ml) via preincubation with media, anti-TLR2 blocking Ab (20mg/
ml), or IgG1 Ab for 30 min; (c) serum-free media, LTA from S. pyogenes (10mg/ml) via preincubation with media, anti-TLR2 blocking Ab
(20mg/ml), or IgG1 Ab for 30 min. Secreted IL-8 was quantified by ELISA from HSC culture supernatant. Data represent the mean7s.d. of
two independent experiments performed in triplicate. *, z: Po0.01, when compared to control HSCs without stimulation; w, y: Po0.01,
compared to HSCs with stimulation after preincubation with IgG1 Ab;.**: Po0.01, unprimed HSCs vs TNF-a-primed HSCs.
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exists between TLRs and receptors for TNF-a and
IL-1b signaling in HSCs.
Our study demonstrates that human HSCs are
equipped with receptors for gram-positive bacterial
products such as PGN and LTA, including TLR2 and
CD14, which activate NF-kB and produce proin-
flammatory IL-8 in response to PGN and LTA. In
addition, we showed an upregulation of TLR2 by
priming HSCs with inflammatory cytokines, such as
TNF-a and IL-1b, and the subsequent enhancement
of NF-kB activation and IL-8 production in response
to PGN and LTA treatment. These results suggest
that TLR2 signaling may be an important therapeu-
tic target for hepatic inflammation and fibrosis,
especially in patients with ongoing chronic hepatic
inflammation.
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